Prospective, multicenter and open clinical study for the efficacy, safety, anorectal morphology and hemodynamics of Shaobei injection in the treatment of hemorrhoids.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023461

Enrollment

Unknown

Registered

2019-05-29

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degree I, II and III internal hemorrhoids

Interventions

1:Shaobei injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, gender is not limited; 2. Patients of grade I, II and III internal hemorrhoids accompanied by bleeding or prolapse; 3. Subjects voluntarily sign written informed consents; 4. Good compliance.

Exclusion criteria

Exclusion criteria: 1. Those who received sclerotherapy or Xiaozhiling injection within three months before the trial; 2. Patients with acute incarcerated hemorrhoids or thrombosis; 3. Complicated with anal fistula, anal fistula and intestinal cancer; patients with other malignant tumors; 4. Patients with other diseases or using other drugs that may interfere with the evaluation of efficacy or safety of drugs in the clinical trial; 5. Received other clinical trials within 6 months before the start of the trial; 6. Pregnant or lactating women; 7. Researchers argue that those who should not be included.

Design outcomes

Primary

Measure	Time frame
Clinical cure rate after treatment;	—

Secondary

Measure	Time frame
Comprehensive effect of simple drug injection therapy;Anorectal morphology and hemodynamic parameters before and after treatment;	—

Countries

China

Contacts

Public ContactRen Donglin

rendl111@163.com+86 13600001818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026